HIGHLIGHTSAn additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate ...

The latest announcement is out from Amplia Therapeutics ( ($AU:ATX) ). Amplia Therapeutics announced a positive development in its ACCENT trial ...

In a bold move, the Chief Minister of Assam has announced that splitting the Dima Hasao district into two is under serious consideration. Conversations with the North Cachar Hills Autonomous Council ...

The FDA has approved Boehringer Ingelheim's nerandomilast as a treatment for idiopathic pulmonary fibrosis (IPF), giving the company a successor to its blockbuster therapy Ofev. Phosphodiesterase (PDE ...

Building on positive Phase 2 data, Puretech plans to launch a Phase 3 trial to further evaluate its experimental IPF therapy ...

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at ...

Betty Aborah won the 2025 EPF European Junior Classic Powerlifting Championships and set a new U63KG Raw Deadlift IPF World ...

In November 2025, IARC, through the World Health Organization, designated the endocrine-disrupting herbicide atrazine as “probably carcinogenic to humans.” ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.